Form 4: Veracyte CFO Sells Shares Under 10b5-1 Plan

Veracyte's Chief Financial Officer, Rebecca Chambers, sold a total of 18,341 shares of common stock on March 4, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), reported the sale of 18,341 shares of common stock.
• The sales occurred on March 4, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2025.
• The first transaction involved 4,400 shares sold at a weighted average price of $35.5476, with individual sale prices ranging from $35.00 to $35.99.
• The second transaction involved 13,941 shares sold at a weighted average price of $36.3288, with individual sale prices ranging from $36.01 to $36.55.
• Following these transactions, Rebecca Chambers beneficially owns 131,196 shares of Veracyte common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine transaction executed under a pre-arranged 10b5-1 plan, which typically does not signal a change in the company's fundamental outlook or performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are pre-scheduled transactions designed to allow insiders to sell shares without being accused of trading on material non-public information. Such routine sales are common and typically do not reflect a change in management's outlook on the company's prospects, distinguishing them from unscheduled, opportunistic sales.

Stakeholder Impact

• Shareholders: May observe a minor, routine insider sale, which is generally not considered a significant indicator of future company performance due to the pre-arranged nature of 10b5-1 plans.

Key Dates

Recommendation

A routine insider sale executed under a Rule 10b5-1 plan, as disclosed in this Form 4, typically does not provide new material information that would warrant a change in an investment recommendation. These sales are pre-scheduled and often part of an insider's personal financial planning, rather than a reflection of a change in the company's fundamental prospects. Investors should continue to evaluate Veracyte based on its operational performance, financial results, and strategic initiatives.

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Rebecca Chambers, CFO, Stock Sale, 10b5-1 Plan